These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21733715)

  • 1. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.
    Porta C; Szczylik C; Escudier B
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):323-37. PubMed ID: 21733715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapy for advanced renal carcinoma: trials in progress.
    Calabrò F; Sternberg CN
    Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapy of kidney cancer with biomolecular drugs.
    Di Lorenzo G; Buonerba C; Biglietto M; Scognamiglio F; Chiurazzi B; Riccardi F; Cartenì G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S16-20. PubMed ID: 21129605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination systemic therapy for advanced renal cell carcinoma.
    Miller RE; Larkin JM
    Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
    Biswas S; Eisen T
    Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel investigative approaches for advanced renal cell carcinoma.
    Berg WJ; Divgi CR; Nanus DM; Motzer RJ
    Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha for the treatment of advanced renal cancer.
    Ravaud A; Dilhuydy MS
    Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
    Figlin RA
    Immunotherapy; 2014; 6(3):261-8. PubMed ID: 24354908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.